

In the claims:

Please cancel claims 21-29 without prejudice.

Please amend the claims as follows:

Claim 1. (currently amended) A method for ~~treatment of neurological or immunological disorders~~ treating a patient exhibiting a symptom of autistic disorder or pervasive development disorder in a patient comprising the step of stimulating secretion of pancreatic juices in said patient.

Claim 2. (currently amended) The method of claim ~~2~~ 1 wherein the step of stimulating secretion of pancreatic juices comprises the step of administering to said patient an ~~effective~~ amount of secretin effective to stimulate secretion of the pancreatic juices.

Claim 3. (original) The method of claim 2 wherein said effective amount of secretin is administered by infusion.

Claim 4. (original) The method of claim 3 wherein administering said effective amount of secretin by infusion includes the step of intravenously infusing secretin in an amount of about 2 clinical units (CU) re kilogram (kg) of body weight.

Claim 5. (original) The method of claim 2 wherein said effective amount of secretin is administered transdermally.

Claim 6. (currently amended) The method of claim 5 wherein administering said effective amount of secretin transdermally includes the steps of:

applying a transdermal carrier ~~substance~~ to a portion of the skin of said patient; and
applying crystalline secretin in said effective amount onto said transdermal carrier ~~substance~~.

Claim 7. (currently amended) The method of claim 6 wherein said transdermal carrier ~~substance~~ includes dimethyl sulfoxide (DMSO).

Claim 8. (original) The method of claim 6 wherein said effective amount of secretin includes between 5 and 20 clinical units (CU) of crystalline secretin per dose.

Claim 9. (currently amended) The method of claim 6 wherein said transdermal carrier ~~substance~~ is selected from the group consisting of a gel and a lotion.

Claim 10. (original) The method of claim 5 wherein administering secretin transdermally includes administering said effective amount of secretin with a patch to be applied to a portion of the skin of said patient.

Claim 11. (original) The method of claim 5 wherein administering secretin transdermally includes administering said effective amount of secretin using acoustic waves causing said secretin to permeate a skin surface of said patient.

Claim 12. (original) The method of claim 2 wherein said effective amount of secretin is administered orally.

Claim 13. (original) The method of claim 12 wherein said effective amount of secretin is administered orally using an oral carrier selected from the group consisting of a tablet, capsule or lozenge.

Claim 14. (original) The method of claim 2 wherein said effective amount of secretin is administered using a suppository.

Claim 15. (original) The method of claim 2 wherein said effective amount of secretin is administered by inhalation.

Claim 16. (currently amended) The method of claim 2 wherein said ~~neurological disorders~~ patient suffers from autistic disorder or pervasive development disorder ~~include autistic spectrum disorders~~.

Claim 17. (currently amended) The method of claim 2 wherein said effective amount of secretin includes an amount of secretin sufficient to increase serotonin levels in the brain of said patient to a level effective to stimulate secretion of the pancreatic juices.

Claim 18. (currently amended) The method of claim 1 wherein stimulating secretion of said pancreatic juices increases at least one neuropeptide hormone ~~select~~ selected from the group consisting of serotonin, dopamine and CCK levels in said patient.

Claim 19. (original) The method of claim 1 wherein the step of stimulating secretion of pancreatic juices includes the step of causing secretion of an effective amount of secretin in said patient.

Claim 20. (currently amended) The method of claim 19 wherein the step of causing secretion of an effective amount of secretin in said patient includes stimulating the duodenum of said patient to ~~produces~~ produce secretin.

Claims 21-29 (withdrawn)

Claim 30.(original) A method for the treatment of autism comprising the step of administering to said patient an effective amount of secretin.

Claim 31.(original) The method of claim 30 wherein said effective amount of secretin is administered by infusion.

Claim 32. (original) The method of claim 31 wherein administering said effective amount of secretin by infusion includes the step of intravenously transfusing secretin in an amount of about 2 clinical units (CU) per kilogram (kg) of body weight per dose.

Claim 33. (original) The method of claim 30 wherein said effective amount of secretin is administered transdermally.

Claim 34. (currently amended) The method of claim 33 wherein administering said effective amount of secretin transdermally includes the steps of

applying a transdermal carrier ~~substance~~ to a portion of the skin of said patient; and applying crystalline secretin in said effective amount onto said transdermal carrier ~~substance~~.

Claim 35.(currently amended) The method of claim 34 wherein said transdermal carrier ~~substance~~ includes dimethyl sulfoxide (DMSO).

Claim 36. (currently amended) The method of claim 35 wherein said effective amount of secretin includes about 15 clinical units (CU) of crystalline secretin per dose.

Claim 37. (new) The method of claim 11, wherein the acoustic waves are generated by low-frequency ultrasound of greater than about 20 kHz.

Claim 38.(new) The method of claim 11, wherein the low-frequency ultrasound is generated for at least about two minutes.

Claim 39. (new) The method of claim 11, wherein the acoustic waves are generated by a shockwave from a pulsed laser.
